1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol 

 Chemical QC [ N.D. P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol 

 Agonist: 0.024 Antagonist: 0.036

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−05−7 : Bisphenol A 

 Chemical QC [ P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−05−7 : Bisphenol A 

 Agonist: 0 Antagonist: 0.14

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−53−1 : Diethylstilbestrol 

 Chemical QC [ P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−53−1 : Diethylstilbestrol 

 Agonist: 0 Antagonist: 0.1

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13311−84−7 : Flutamide 

 Chemical QC [ N.D. P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13311−84−7 : Flutamide 

 Agonist: 0 Antagonist: 0.23

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52806−53−8 : Hydroxyflutamide 

 Chemical QC [ P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52806−53−8 : Hydroxyflutamide 

 Agonist: 0 Antagonist: 0.55

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−55−9 : p,p'−DDE 

 Chemical QC [ N.D. N.D. N.D. ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−55−9 : p,p'−DDE 

 Agonist: 0.042 Antagonist: 0.064

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32809−16−8 : Procymidone 

 Chemical QC [ P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32809−16−8 : Procymidone 

 Agonist: 0 Antagonist: 0.17

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50471−44−8 : Vinclozolin 

 Chemical QC [ N.D. N.D. N.D. P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50471−44−8 : Vinclozolin 

 Agonist: 0 Antagonist: 0.2

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Antagonist

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−05−8 : 4−Androstene−3,17−dione 

 Chemical QC [ N.D. P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

63−05−8 : 4−Androstene−3,17−dione 

 Agonist: 0.83 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Agonist

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

521−18−6 : 5alpha−Dihydrotestosterone 

 Chemical QC [ P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

521−18−6 : 5alpha−Dihydrotestosterone 

 Agonist: 1.1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2392−39−4 : Dexamethasone sodium phosphate 

 Chemical QC [ N.D. P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

2392−39−4 : Dexamethasone sodium phosphate 

 Agonist: 0.22 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−18−4 : 17−Methyltestosterone 

 Chemical QC [ N.D. P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−18−4 : 17−Methyltestosterone 

 Agonist: 1.1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Agonist

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−85−2 : Testosterone propionate 

 Chemical QC [ N.D. P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−85−2 : Testosterone propionate 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Agonist

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−28−2 : 17beta−Estradiol 

 Chemical QC [ P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−28−2 : 17beta−Estradiol 

 Agonist: 0.79 Antagonist: 0.06

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

427−51−0 : Cyproterone acetate 

 Chemical QC [ N.D. P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

427−51−0 : Cyproterone acetate 

 Agonist: 0.26 Antagonist: 0.069

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−16−7 : Estrone 

 Chemical QC [ N.D. P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−16−7 : Estrone 

 Agonist: 0.074 Antagonist: 0.26

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

206−44−0 : Fluoranthene 

 Chemical QC [ N.D. N.D. N.D. ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

206−44−0 : Fluoranthene 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−55−2 : Linuron 

 Chemical QC [ P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−55−2 : Linuron 

 Agonist: 0 Antagonist: 0.044

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−83−0 : Progesterone 

 Chemical QC [ P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−83−0 : Progesterone 

 Agonist: 0.56 Antagonist: 0.077

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−01−7 : Spironolactone 

 Chemical QC [ N.D. N.D. N.D. ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−01−7 : Spironolactone 

 Agonist: 0.054 Antagonist: 0.29

Concentration (uM)

Receptor Score

Agonist: SARM

Antagonist: SARM

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1912−24−9 : Atrazine 

 Chemical QC [ P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1912−24−9 : Atrazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−81−7 : Di(2−ethylhexyl) phthalate 

 Chemical QC [ P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−81−7 : Di(2−ethylhexyl) phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−74−2 : Dibutyl phthalate 

 Chemical QC [ P P P P P ]

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−74−2 : Dibutyl phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

Antagonist: Inactive